Data and code to reproduce these analyses are available as an R package from GitHub (<https://github.com/petermacp/hiv.prospect>).

Introduction {#sec005}
============

The deadline of the Joint United Nations Programme 90-90-90 campaign to end the HIV epidemic by 2020 is approaching.\[[@pone.0236407.ref001]\] Substantial global progress has been made with seven countries having reached the target of achieving high coverage of viral suppression amongst all people living with HIV.\[[@pone.0236407.ref002]\] Malawi is among the large proportion of countries still striving to reach these targets.

Through initiatives such as provider-initiated testing and counselling (PITC), and with the strong support of the Malawi National HIV Programme, 70% of Malawians knew their status in 2016.\[[@pone.0236407.ref002]\] Despite this being an improvement on previous years, there remains substantial room for further improvement.

Current Malawian National Guidelines focus on facility testing and community testing as priority opportunities for HIV testing and diagnosis.\[[@pone.0236407.ref003]\] PITC is recommended for anyone attending healthcare facilities including outpatient departments as one of the most effective strategies for identifying new HIV diagnoses. Other strategies recommended include index testing and self-testing. \[[@pone.0236407.ref003]\] Community-based HIV testing strategies have helped to reach the "untested" population, including key populations with high HIV prevalence that are hard to reach, such as men who have sex with men, female sex workers, people who inject drugs, and transgender women.\[[@pone.0236407.ref004]\] Despite impressive achievements in increasing community-based strategies, the majority of HIV testing still occurs in health facilities. PITC in health facilities remains a critical strategy for identifying and linking to care people with advanced HIV and concomitant high risk of death. When investigated previously in Blantyre, Malawi in 2011 only 13% of all adult clinic attenders completed PITC, leading to many missed opportunities for diagnosis and linkage to ART.\[[@pone.0236407.ref005]\]

New strategies for improving rates of HIV test offer within health facilities are essential to help reach the untested population. One strategy is routine opt-out (ROOT) HIV testing in which patients are offered an HIV test at each clinic visit unless they specifically refuse.\[[@pone.0236407.ref006]\] A further is utilising semi-supervised oral fluid based HIV testing kits within facilities.\[[@pone.0236407.ref007]\]

Patients presenting with symptoms of tuberculosis (TB)--cough (of any duration), fever, weight loss and night sweats--have a high prevalence of undiagnosed HIV and advanced immunosuppression.\[[@pone.0236407.ref008]\] In fact, in settings with generalised HIV epidemics those presenting with TB symptoms have higher prevalence of HIV than people with confirmed TB.\[[@pone.0236407.ref009]\] Despite the high HIV prevalence in patients with TB symptoms, they are not listed as a priority screening group in the Malawian National Strategic Plan for HIV and AIDS.\[[@pone.0236407.ref010]\]

This study investigated PITC uptake for those with and without TB symptoms at a busy primary health care centre in Malawi. The objectives were to describe the fraction of acute adult clinic attenders who were offered and received HIV testing and counselling, and to explore risk factors associated with non-completion of PITC.

Methods {#sec006}
=======

Study design and participants {#sec007}
-----------------------------

We undertook a prospective study among adults (18 years or older) attending Bangwe Health Centre (BHC) with an acute illness between 21^st^ May 2018 and 6^th^ September 2018. BHC is a busy public primary health care clinic located in urban Blantyre, Malawi, where adult HIV prevalence is 18%\[[@pone.0236407.ref011]\] and TB prevalence approximately 1%.\[[@pone.0236407.ref012]\] This study was nested within the pilot phase of a pragmatic randomised trial being conducted at the clinic that aims to evaluate strategies to optimise diagnosis and treatment initiation for HIV and tuberculosis. \[[@pone.0236407.ref013]\]

BHC has an adult outpatient department where community members can self-present and are registered and receive care free-of-charge for illnesses. Within BHC, there are additionally HIV, TB, antenatal, and paediatrics departments from where we did not recruit study participants. At BHC there are no physicians; medical care is provided by nurses and clinical officers. PITC is recommended by the Malawi National HIV Programme for all attendances to an outpatient department, and was available at BHC, provided by Ministry of Health-accredited counsellors. ART and antituberculosis therapy were provided onsite at the HIV care clinic and TB clinic respectively. Sputum smear microscopy and GeneXpert MTB/Rif testing were available onsite in the clinic laboratory. Patients requiring chest X-ray for investigation of possible TB required healthcare referral to the city's central hospital.

Screening and exit interviews {#sec008}
-----------------------------

Research assistants stationed at the clinic's outpatient department registration desk identified all adult individuals attending the clinic to receive acute care. Following verbal consent, a fingerprint scan was recorded for bioidentification. Research assistants then undertook a brief screen, recording clinic attenders' age, sex and the presence of TB symptoms (cough and cough duration, fever, weight loss, and night sweats). Information was not recorded from participants who declined fingerprint scanning. Following the completion of screening, clinic attenders joined the outpatient department queue to be seen by health workers.

Next, participants were reviewed by a health worker. Health workers worked independently from research assistants and were unaware of the results of questions asked during initial screening. Health workers were not required to screen for TB symptoms as part of study protocol, however it is recommended in national and WHO guidelines that all clinic attenders be: 1) Screened for TB symptoms and 2) Offered PITC.\[[@pone.0236407.ref014]\]

Research assistants were also based at the two clinic outpatient department exits, where they identified adults leaving the department and invited them to participate in an exit interview. The layout of the clinic is such that all participants exiting the clinic would pass the research assistants. Though researchers tried to select as many patients as possible, due to limitations in the number of research assistants not all participants completed exit interview. To minimise inconvenience and maximise research assistants' capacity to complete interviews, questionnaires were brief with predominantly binary responses to questions rather than in-depth qualitative questions. Prior to exit interview identity was verified by fingerprint bioidentification. Clinic attenders were asked about the care they received whilst in the clinic, including whether they had been offered HIV testing, and whether HIV testing had been completed during their clinic visit. We additionally recorded whether participants had ever previously tested for HIV, their self-reported HIV and ART status, and whether they had previously been treated for TB.

Statistical methods {#sec009}
-------------------

We summarised characteristics of clinic attenders using proportions, medians and means, and compared them between those who did and did not undergo clinic exit interview. Individuals who reported cough of any duration, fever, weight loss, or night sweats were classified as having "any TB symptom". Cough duration was also recorded and in accordance with WHO guidelines, we defined chronic cough as self-reported cough lasting greater than two weeks.

Participants with known HIV-positive status who were already taking ART were excluded from the analysis. Those with self-reported HIV positive status who were not taking ART were included as this provides further opportunity for confirmatory testing and linkage to ART. We summarised the proportion of clinic attenders who reported having been offered an HIV test and who reported having completed an HIV test on the same day as their visit, and compared groups by demographic and clinical characteristics. As previous research suggests men have a higher burden of undiagnosed TB and present later for diagnoses than women, results were stratified by sex to investigate differences between sexes. \[[@pone.0236407.ref008]\]

To investigate characteristics associated with reporting completing HIV testing during a clinic visit exit interview, we constructed Bayesian multivariable logistic regression models.\[[@pone.0236407.ref015]\] Initial models included terms for age and sex, and subsequent models evaluated the incremental improvement in model fit from adding reported history of previous TB treatment and having previously tested for HIV. We then constructed models including terms for the presence of either: cough; chronic cough; or any TB symptoms. Weakly regularising priors were applied to model intercepts and slopes. Convergence was evaluated by inspecting trace plots and effective sample numbers, and by calculating Gelman-Rubin statistics. Model fits were compared using the Watanabe-Akaike information criteria (WAIC) statistic and weights.

Three thousand samples were drawn from each model posterior distribution using Markov Chain Monte Carlo methods implemented within Stan. Model coefficients on the log-odds scale were exponentiated to give odds ratios, and posterior means and 89% probability intervals were calculated and plotted. Posterior predictions for age and sex were graphed, stratified by presence of TB symptoms (cough, chronic cough, any TB symptom). Analysis was conducted using R version 3.5.2 (R Foundation for Statistical Computing, Vienna).

Ethical approval {#sec010}
----------------

Ethical approval was received from the College of Malawi Research Ethics Committee (COMREC), and from the Liverpool School of Tropical Medicine Research Ethics Committee. Individuals undergoing exit interviews provided written (or witnessed thumb-print if illiterate) consent.

Data and reproducibility {#sec011}
------------------------

Data and code to reproduce these analyses are available as an R package from <https://github.com/petermacp/hiv.prospect>.

Results {#sec012}
=======

Characteristics of clinic attenders {#sec013}
-----------------------------------

Between 21^st^ May and 6^th^ September 2018, a total of 5427 adult acute attendances were recorded at the study clinic. Five individuals declined fingerprint identification and were not included in the study. Of the remaining 5422 attendances, 4895 (90%) were by individuals who attended the clinic only once during the study period, and 527 (10%) by individuals who attended more than once; the maximum number of clinic attendances during the study period was seven, recorded by one individual. The number of daily acute clinic attendances recorded ranged between 41 and 106 (mean = 70.4, median = 69).

Overall, 64% (3486/5422) of clinic attendance episodes were by women, with similar age distributions between women (median: 28 years, range: 18--88) and men (median: 28 years, range: 18--89)--[Table 1](#pone.0236407.t001){ref-type="table"}. Women and men attending the clinic had similar distributions of reported: cough of any duration (women: 1135, 33%; men: 686, 35%); chronic cough (women: 218, 11.3%; men: 304, 8.7%); weight loss (women: 431, 12.4%; men: 281, 14.5%); fever (women: 951, 27.3%; men: 630, 32.5%); night sweats (women: 596, 17.1%; men: 388: 20.0%); and any TB symptom (women: 1905 (54.6%; men: 1111 (57.4%). Overall, 1.4% (77/5422) of clinic attenders reported being currently treated for TB (women: 48, 1.4%; men: 29, 1.5%).

10.1371/journal.pone.0236407.t001

###### Characteristics of adult acute clinic attendances.

![](pone.0236407.t001){#pone.0236407.t001g}

                       Exit Interviewed (N = 2397)   Not Exit Interviewed (N = 3025)   Total (N = 5422)
  -------------------- ----------------------------- --------------------------------- ------------------
  Sex                                                                                  
      Female           1497 (42.9%)                  1989 (57.1%)                      3486 (100.0%)
      Male             900 (46.5%)                   1036 (53.5%)                      1936 (100.0%)
  Age                                                                                  
      Median (Range)   28 (18, 89)                   27 (18, 89)                       28 (18, 89)
  Cough                                                                                
      No               1548 (43.0%)                  2053 (57.0%)                      3601 (100.0%)
      Yes              849 (46.6%)                   972 (53.4%)                       1821 (100.0%)
  Weight Loss                                                                          
      No               2081 (44.2%)                  2629 (55.8%)                      4710 (100.0%)
      Yes              316 (44.4%)                   396 (55.6%)                       712 (100.0%)
  Fever                                                                                
      No               1663 (43.3%)                  2178 (56.7%)                      3841 (100.0%)
      Yes              734 (46.4%)                   847 (53.6%)                       1581 (100.0%)
  Night Sweats                                                                         
      No               1936 (43.6%)                  2502 (56.4%)                      4438 (100.0%)
      Yes              461 (46.8%)                   523 (53.2%)                       984 (100.0%)
  Any TB Symptom^†^                                                                    
      No               1027 (42.7%)                  1379 (57.3%)                      2406 (100.0%)
      Yes              1370 (45.4%)                  1646 (54.6%)                      3016 (100.0%)
  Chronic Cough^¶^                                                                     
      No               2176 (44.4%)                  2724 (55.6%)                      4900 (100.0%)
      Yes              221 (42.3%)                   301 (57.7%)                       522 (100.0%)

† Any TB symptom: cough, or weight loss, or fever, or weight loss.

¶ Cough of 14 days or longer

A total of 2397 (44%) clinic attendances were followed by same-day study exit interviews. Characteristics between clinic attenders who did and did not complete exit interviews were similar, but with some differences ([Table 1](#pone.0236407.t001){ref-type="table"}). Women (1497, 42.9%) were less likely to complete exit interviews than men (900, 46.5%). Additionally, clinic attenders who reported any TB symptom were more likely to complete an exit interview compared to clinic attenders who didn't (45.4% vs 42.7%). This was consistent for cough, fever, weight loss and night sweats. However those with chronic cough were less likely to complete exit interview than those without (42.3% vs 44.4%).A total of 276 (11.5%) clinic attenders reported that they were HIV positive and taking ART and were exclude from regression modelling.

Of 2121 patients included in the analysis 1907 (89.9%) self-reported previously ever testing for HIV, in comparison to 214 (10.1%) who self-reported never testing. Females (1194/1295, 92.2%) were more likely to self-report previous HIV testing than males (713/826, 86.3%). Previous testers (median: 27 years, range 18--87), were of similar age to non-testers (mean: 26 years, range 18--89).

Offer and completion of HIV testing {#sec014}
-----------------------------------

A total of 585/2121 (27.6%) eligible participants reported being offered HIV testing by a health worker during their clinic attendance, and 455/2121 (21.5%) completed HIV testing. Twenty-nine percent of men (242/826) and twenty-six percent (343/1295) of women were offered HIV testing by health workers. Those offered HIV testing were younger than those not (median age: 26 vs. 29 years respectively). There were few differences in the proportions offered HIV testing among participants who reported and did not report TB symptoms (any TB symptom: 348/1199, 29.0% vs. 237/922, 25.7%; cough: 211/732, 28.8% vs. 374/1389, 26.9%; chronic cough: 39/179, 21.7% vs. 546/1942, 28.1%; weight loss: 74/252, 29.3% vs. 511/1869, 27.3%; fever: 190/647, 29.3% vs. 395/1474, 26.8%; night sweats: 104/407, 25.6% vs. 481/1714, 28.1%). Participants who reported previously having been treated for TB were less likely to be offered HIV testing (16/78, 20.5%) than those not previously treated for TB (569/2043, 27.9%). Participants who self-reported previously testing for HIV were more likely to be offered testing (539/1907, 28.3%), than those who had not previously HIV tested (46/214, 21.5%).

In addition to being more likely to be offered HIV testing, men (184/242, 76.0%) were more likely to report completing HIV testing compared to women (252/343, 73.4%). Age was also associated with completion of HIV testing, with the median age of those completing testing (26 years) lower than those who didn't complete HIV testing (29 years). Similarly, patterns of completion of HIV testing among those with and without TB symptoms closely mapped data for offer of HIV testing (cough: 165/211, 78.2% vs. 271/374, 72.5%; chronic cough: 28/39, 71.8% vs. 408/546, 74.7%; weight loss: 54/74, 73.0% vs. 382/511, 74.8%; fever: 135/190, 71.1% vs. 301/395, 76.2%; night sweats: 74/104, 71.2%% vs. 362/481, 75.3%; any TB symptom: 254/348, 73.0% vs. 182/237, 76.8%). Participants who had previously been treated for TB (9/16, 56.25%) were less likely to complete HIV testing than those hadn't previously been treated (427/659, 75.0%). Participants who self-reported previous HIV testing were likelier to completing testing (417/539, 77.4%) than those who had not (19/46, 41.3%).---([Fig 1](#pone.0236407.g001){ref-type="fig"}).

![Percentages of participants offered and completing HIV testing by TB symptoms.\
Proportions of patients offered HIV testing. Stratified by those with TB symptoms (top row) and those without TB symptoms (bottom row).](pone.0236407.g001){#pone.0236407.g001}

In the initial regression model ([Table 2](#pone.0236407.t002){ref-type="table"}, Model 1), men were more likely to complete HIV testing than women (posterior odds ratio: 1.15, 89% interval: 0.97--1.37), and older participants were less likely to complete HIV testing (posterior odds ratio per year increase in age: 0.99, 89% interval: 0.98--0.99). Models that included terms for cough (Models 2a, 2b and 2c) additionally showed that reporting cough, and having previously tested for HIV increased the posterior odds of HIV testing, whilst previously being treated for TB decreased the posterior odds of completing HIV testing. In contrast, having chronic cough instead of cough (Models 3a, 3b, 3c) resulted in a reduced posterior odds ratio of completing HIV testing. Reporting any TB symptom (Models 4a, 4b and 4c) was linked to a reduced posterior odds ratio for completing HIV testing. Models that included terms for age, sex, previous HIV testing, previous TB treatment, and either cough, chronic cough or any TB symptom (Models 2c, 3c and 4c) had the lowest WAIC statistics and greatest weight. Model summary estimates are provided in [Table 2](#pone.0236407.t002){ref-type="table"} and visually in [Fig 2](#pone.0236407.g002){ref-type="fig"}.

![Model posterior probabilities for completing HIV testing during clinic attendance for individuals with and without TB symptoms.](pone.0236407.g002){#pone.0236407.g002}

10.1371/journal.pone.0236407.t002

###### Model posterior probabilities of completing HIV testing during clinic visit.
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                        Posterior probability (mean odds ratio, 89% interval)                                                                                                                                                                   
  --------------------- ------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  Intercept             0.35 (0.25--0.49)                                       0.28 (0.19--0.42)   0.51 (0.26--1.00)   0.06 (0.02--0.16)   0.35 (0.25--0.50)   0.62 (0.33--1.18)   0.07 (0.03--0.20)   0.42 (0.28--0.62)   0.76 (0.39--1.55)   0.09 (0.03--0.24)
  Male sex              1.15 (0.97--1.37)                                       1.15 (0.96--1.36)   1.16 (0.97--1.39)   1.23 (1.01--1.42)   1.16 (0.98--1.39)   1.17 (0.99--1.39)   1.24 (1.04--1.49)   1.15 (0.97--1.36)   1.17 (0.99--1.38)   1.23 (1.05--1.46)
  Age (Per Year)        0.99 (0.98--0.99)                                       0.98 (0.98--0.99)   0.99 (0.98--0.99)   0.99 (0.98--0.99)   0.99 (0.98--0.99)   0.99 (0.98--0.99)   0.99 (0.98--0.99)   0.98 (0.98--0.99)   0.99 (0.98--0.99)   0.99 (0.98--0.99)
  Previous TB                                                                                       0.53 (0.29--0.91)   0.50 (0.28--0.84)                       0.56 (0.31--0.99)   0.52 (0.28--0.90)                       0.54 (0.31--0.91)   0.50 (0.28--0.86)
  Ever Tested For HIV                                                                                                   3.02 (2.10--4.43)                                           2.96 (2.05--4.46)                                           3.02 (2.07--4.41)
  Cough                                                                         1.21 (1.02--1.44)   1.22 (1.03--1.46)   1.24 (1.04--1.47)                                                                                                       
  Chronic Cough                                                                                                                             0.82 (0.59--1.14)   0.84 (0.60--1.17)   0.84 (0.58--1.18)                                           
  Any TB Symptom                                                                                                                                                                                        0.90 (0.76--1.06)   0.90 (0.75--1.07)   0.88 (0.74--1.05)
  WAIC\*                2196.0                                                  2194.9              2193.6              2169.7              2197.3              2196.7              2173.2              2196.9              2195.7              2171.9
  Weight                0.00                                                    0.00                0.00                0.66                0.00                0.00                0.12                0.00                0.00                0.22

\*WAIC = Watanabe-Akaike information criteria

When converted to the probability scale, there was strong evidence of decreased probability of completing HIV testing with increasing age across all three models that included terms for TB symptoms (Models 2c, 3c and 4c). Additionally, the posterior probability of HIV testing was consistently higher among men than women, as well as those with a prior self-reported history of HIV testing. ([Fig 3](#pone.0236407.g003){ref-type="fig"}).

![Predicted probability of HIV testing by age and sex.\
Predicted probabilities are estimated from multivariable Bayesian regression models, adjusted for no history of previous TB and not having tested previously for HIV.](pone.0236407.g003){#pone.0236407.g003}

Discussion {#sec015}
==========

The findings of our study reveal that less than one-third (27.6%) of adults attending a primary health care clinic with an acute care episode were offered an HIV test, and only 21.4% completed same-day HIV testing. Despite this being an improvement on when previously examined in Blantyre in 2010 (13%), \[[@pone.0236407.ref005]\] this study reveals many missed opportunities for HIV testing and diagnosis. This highlights lack of implementation of national guidelines, which state that all patients attending an outpatient appointment should be offered an HIV test.

A recent overview of delivery of facility-based HIV testing services in Malawi showed that the majority of health centres use symptom-based PITC, with more unwell people prioritised for HIV testing.\[[@pone.0236407.ref016]\] Understanding the rationale for this and developing new strategies are key for further improvement. Previous qualitative research has revealed that health care workers felt more compelled to provide PITC in ANC than in outpatients departments.\[[@pone.0236407.ref017]\] Healthcare workers also saw ART as a precious resource which should be reserved for those who were more unwell in outpatient departments. Utilising symptom-based PITC leads to detection of patients later in their disease course with greater risk of suboptimal HIV treatment outcomes. Moreover, certain groups who are difficult to reach through existing programmes and who have higher rates of undiagnosed HIV (such as older people) are disadvantaged.

Changes in approach are needed to reduce further missed opportunities for testing. One strategy would be to include a ROOT approach in national guidelines whereby patients are offered an HIV test for every acute care attendance unless they decline, potentially leading to higher uptake of HIV testing. \[[@pone.0236407.ref006]\] Using the ROOT approach is resource intensive and common barriers to reaching 100% coverage include limited health worker capacity, inadequate space in facilities, and insufficient test kits.\[[@pone.0236407.ref005],[@pone.0236407.ref016]\] These stated limitations may account for the population of patients in our study who were offered HIV testing but did not undergo a test.

A second approach would be utilising semi-supervised oral fluid-based rapid HIV self-testing kits within facilities to help overcome some of these barriers. This has previously been implemented with success in a rural African setting with high rates of accuracy and user acceptance.\[[@pone.0236407.ref007]\] Qualitative research has suggested that patients who noticed a decline in their health, may wish to know their status and therefore may be motivated to test themselves.\[[@pone.0236407.ref017]\] This strategy may be key to removing the heavy burden of work on the healthcare workers and empowering patients to know their own status.

In generalised HIV epidemics, people with symptoms of TB have a high prevalence of HIV at all levels of healthcare; including community level, primary health care and hospital inpatients.\[[@pone.0236407.ref009]\] In acknowledgement of these patients being a high risk group, WHO policy on collaborative TB/HIV activities was updated in 2012 to advise that in generalised HIV epidemics routine HIV testing should be offered to all with presumptive or diagnosed TB.\[[@pone.0236407.ref018]\]

Contrary to our expectation of higher HIV testing completion among people with TB symptoms, we found that the presence of TB symptoms--defined by either cough of any duration, chronic cough, or any TB symptom--was not associated with HIV testing; in fact having any TB symptom reduced posterior odds of completing HIV testing. Considering over 50% of clinic attenders in our study reported symptoms of TB, our findings suggest large numbers of missed opportunities for new diagnoses of HIV and linkage to ART.

The Malawian Ministry of Health National Tuberculosis Control Programme recommends PITC HIV testing for all patients with presumptive TB.\[[@pone.0236407.ref019]\] This issue is also recognised in the Malawian National Strategic Plan for HIV AIDS 2015--2020 which suggests PITC HIV testing should be moved upstream to include patients with suspected TB as well as confirmed TB; however this is not listed as a priority intervention.\[[@pone.0236407.ref010]\] The findings in this study combined with review of the literature suggest patients with TB symptoms should be list as a priority intervention for expanding PITC, and further collaboration is needed between TB and HIV coordinators at a national level.

With the maturation of the HIV epidemic in Southern Africa, the prevalence of HIV (and undiagnosed HIV) is growing among older adults.\[[@pone.0236407.ref020]\] This key population, who often remain sexually active, are challenging to reach with community-based HIV testing interventions.\[[@pone.0236407.ref021]\] Our study shows facility rates of offering and acceptance of HIV testing decreased with increasing age, again suggesting missed opportunities for HIV diagnoses. Efforts should be made to incorporate HIV testing into guidelines for those with non-communicable diseases, which are likely to be "unmasked" by this aging population. Men were more likely to test than women which could be attributed to presenting later in their disease with more advanced clinical symptoms and therefore triggering symptom-based PITC. Only 41.3% of patients who self-reported having never previously tested were offered PITC. Utilising ROOT can help prevent missing vital opportunities for this population to learn their status.

Participants with a self-reported history of HIV testing have previously undertaken pre and post-test counselling and have overcome barriers of stigma relating to testing. This awareness of the importance of knowing their status may drive them to request further HIV testing from health-workers. This population of frequent HIV testers may also be undertaking higher risk activities or presenting with conditions that demand frequent testing such as sexually transmitted infections.

Our study does have limitations. Firstly due to limited availability of Research Assistants, exit interviews were only performed in 44% of visits potentially resulting in bias in selection of participants. It is possible that participants who were sicker were being referred to same day secondary facilities and were under greater time-pressure and less likely to be stopped or indeed engage with exit interview. Secondly symptoms and HIV testing patterns were self-reported which could result in bias in measurement of outcomes. Thirdly patients were not asked the time since last HIV test in exit interview. Therefore, an analysis of proportion of patients testing annually in accordance with current WHO guidelines could not be performed. Finally, results were taken from one health facility and may not be representative of findings throughout the country and continent.

Conclusion {#sec016}
==========

Same-visit completion of PITC in primary care was poorly implemented, especially among groups known to have high prevalence of undiagnosed HIV (people with TB symptoms, older adults). As countries approach universal coverage of ART, identifying and prioritising currently underserved groups for HIV testing will be essential. Routine opt-out HIV testing needs to be prioritised if HIV programmes are to identify and treat the missing millions with undiagnosed HIV.
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b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Overall

This manuscript describes a prospective cohort study undertaken in an adult primary care clinic in Blantyre Malawi to evaluate whether clinic attendees were offered PITC and to compare same day HIV testing rates between participants reporting TB symptoms vs those reporting no TB symptoms. From other data, rates of undiagnosed HIV are high among clinic clients reporting TB symptoms, therefore should be prioritized for HIV testing. The investigators relied on self-report of HIV-testing upon exit interview, and only 44% of clinic attendees underwent exit interview.

The main finding of the study was that among participants undergoing exit interview, only 27.6% reported being offered testing, with 21.5% completing PITC and receiving HIV test results. Testing offered was relatively similar among those with and without TB symptoms. The multivariable regression model indicated men, younger adults, and participants who had previously undergone HIV-testing were more likely to complete HIV testing than women, older adults, and those who had not previously been tested for HIV.

Although an important topic- universal HIV testing as well as importance of HIV testing among those with TB symptoms, the paper could be strengthened by a number of additions/clarification:

-The authors do not included data regarding proportion of participants who report TB symptoms (and those without TB symptoms) who were diagnosed with HIV. This is an important data point and could be used to support their hypothesis that clinic goers with TB symptoms are a high yield population to test.

-Only 44% of clinic goers underwent exit interview. I wonder if it is possible to also reconstruct the cascade of testing and testing results utilizing the registers from the clinic over the same time period. Although these registers may not include the results of the TB symptom screen, they would provide an objective snapshot of number of clinic goers offered testing, undergoing testing, and testing results and would be very informative.

-Additionally, it appears clinic attendees with TB symptoms were less likely to undergo exit interview. The authors should clarify how this may have biased their results. Perhaps participants who had TB symptoms did under HIV testing, but they weren't captured for some reason in the exit interview?

-Is the reason for clinic appt recorded? If so, would also include in the models of testing. Perhaps certain presenting complaints (or even primary diagnosis of the encounter) are related to testing offer, uptake, and diagnosis.

Introduction/Methods

-Suggest clearly stating what the Malawian guidelines are for testing adults in a primary care clinic are.

-Authors mention these visits are for acute care, but my assumption it is for all-comers. Please clarify

Methods

-If possible, briefly describe what the pragmatic RCT will focus on.

-Describe what the Malawian PITC guidelines are.

-Is TB care provided at the clinic, or are patients referred somewhere else. What are the next steps for patients with TB symptoms at the clinic? Perhaps if they are referred somewhere else this could account for the fact that they were difficult to reach for exit interviews

-Be consistent RE: capitalization for Research Assistant.

-Clarify if PITC is to be offered for those with a negative test \>90 days, or unknown HIV status (these details aren't mention- I'm just assuming this is the guideline).

-Investigators mention excluding known PLHIV who were already taking ART, but what about known PLHIV not yet on ART? Were they also excluded? If so, clarify.

Results

-Are reasons for attendance to clinic, or clinic visit diagnosis available? Per above this may influence HIV testing as well.

-Was clinic flow different for patients who reported TB symptoms? Would they have been tested for HIV at another clinic (i.e. during further TB workup?).

-Were reasons test refusal among those offered testing recorded?

-Was time of last reported test recorded? Consider including in model.

Discussion

\- Mentions that majority of health centers use symptom-based PITC, as opposed to universal offer. Is this in agreement with Malawi PITC guidelines?

-ROOT is mentioned for the first time in the Discussion. Suggest this be brought up earlier in the introduction to frame the reason to do the study.

-Discussion mentions WHO policy is in that setting with generalized epidemics that routine PITC should be offered to all with presumptive or diagnosed TB. Do the Malawian guidelines agree with this?

-The statistic that \>50% of clinic attenders in the study reported TB symptoms is an important one and I'd suggest that this be mentioned in abstract.

-Authors mention that only 44% of participants underwent exit interview as a limitation. One way to overcome this limitation is to include data from registers from the study period regarding TB symptoms (if available), HIV testing offer, and HIV test result. The latter 2 should be in the register.

-Given the data, what do the authors suggest are the next steps?

References

-A minor comment, but please use consistent formatting/spacing in the references.

Table 1

Was any statistical testing done to see if there were differences between adult clinic attendees who had an exit interview or not. Suggest this is done. It appears that overall a lower proportion of participants who had a positive symptom screen underwent an exit interview.

Figure 1

For the top row of graphs please label Men and Women if that is what the Y axis is.

Reviewer \#2: Authors have presented a nice study. They were interested to find out if adult patients seeking urgent care with TB-symptoms would receive PITC (as is recommended by WHO and Malawi National programmes).

Elegantly, they made their observations independent of the care offered at the health care facility (staffed by clinical officer, and nurses). Investigators positioned themselves at a registration desk for adult outpatients. Following verbal consent, identified patients through fingerprint biometrics and asked questions about age, HIV testing history, and TB symptoms.

Then, during exit interviews, 44% of adult patients were linked and patients were asked if an HIV test was offered, and if a test was taken.

Their data showed that contrary to their expectation, patients with TB symptoms were less likely to be tested than patients without TB patients. They also did statistical modeling to predict who would be more likely to be HIV tested.

The findings are clearly presented. This will be a useful contribution to the literature.

I have the following questions that should be addressed in the revision.

1\. Participants were asked if they had ever previously tested for HIV. Can authors clarify if they collected the date of the last HIV test? If they did not, then mention this as a study limitation. If they did, they can provide the proportion who tested in the last year (annual testing for adults of the general population is a WHO recommendation).

2\. Participants were asked their self-reported HIV status and ART status. HIV-positive patients on ART were excluded from the modeling. Can authors present the number of newly diagnosed patients (by self-report)? There should be patients who will have mentioned this, and thee majority will/should have started same day treatment. Unless authors plan to report on self-reported test outcome - but they should say something about self-reported HIV testing at care seeking (as they asked about it). Is it possible that patients with a new HIV diagnosis who were started on ART were not interested to present the exit desk for interview? This should be mentioned as a limitation of this study.

3\. Qualitative data (e.g. focus group discussions with providers) were not collected. I find this another important limitation of the study. It would have been so easy to present result back to providers and ask them why they through that younger patients, men, and patients without TB symptoms were more like to be HIV tested.

Other points that can be clarified / improved upon:

1\. Discussion hinges on two arguments - leading to two proposed strategies. Poor performance of PITC should be improved through targeted testing and ROOT (routine opt out testing).

Poor performance: Vast numbers of patients with TB-symptoms are not tested. These are major missed opportunities. Rather than calling this \"suboptimal\" - be more bold in your conclusion! This is very poor implementation of existing guidelines. Why is that so? that remains unclear. Authors suggest that targeted PITC could be achieved through oral self-testing.

ROOT is presented as a possible if not best strategy. Is this likely? Given that current system under performs?

Perhaps authors can more clearly distinguish the two strategies. Something like \-- targeted PITC should be immediately implemented. ROOT is the preferred strategy but would require substantial resources.

Small points:

PITC HIV testing - misnomer - change to targeted HIV testing.

Is there a reference for ROOT?

Participants with a self-reported HIV testing history may drive them to request further HIV testing. Was this not explored in the exit interview? Were you offered an HIV test? Did you take an HIV test? or Did you ask for an HIV test yourself?

first paragraph discussion - last sentence. Optimism can be taken from an increase of 89.9% to 90.8%. There is either a typo in the stats, but i find this a minimal increase not worth discussing and no reason for optimism.

Last sentence of introduction (stratification by sex) reads as a methods sentence and is better placed in methods.

Approximately 1 in 4 patients is offered testing. And of those offered, 4 out of 5 accept HIV testing. Is it clear why a substantial number of patients refuse testing?

End.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Eduard Sanders

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

23 Apr 2020

Dear Editors and Reviewers,

RE: Provider-initiated HIV testing and TB screening in the era of universal coverage: are the right people being reached? A cohort study in Blantyre, Malawi

I write on behalf of my co-authors to thank the reviewers for their careful review, and appreciate the opportunity to respond with a revised submission. Please see a point-by-point response below.

As recommended by the Reviewers, we have updated the manuscript to provide a more definite conclusion that the study shows poor implementation of national HIV testing guidelines and to emphasise that evaluation of additional strategies for increasing HIV testing rates are needed. The discussion has been expanded to further discuss potential strategies for improvement. This includes implementation of routine opt out HIV testing (ROOT), as well as the use of semi-supervised oral fluid-based HIV tests within facilities.

We hope that with the changes made as suggested by the reviewers this manuscript can be published and provide motivation for a change in HIV testing policy.

Please find attached the requested documents:

\- Manuscript

\- Revised Manuscript with track changes

\- Response To Reviewers

We have also included a copy of the patient questionnaire used during the trial as requested by the editors.

Yours sincerely,

Dr Luke Mair

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0236407.r003
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Provider-initiated HIV testing and TB screening in the era of universal coverage: are the right people being reached? A cohort study in Blantyre, Malawi

PLOS ONE

Dear Dr. Mair,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has improved in clarity but still but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please see the specific suggestions from Reviewer 1 about additional clarification and some minor edits that would improve readability.

We would appreciate receiving your revised manuscript by Jul 02 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Susan Marie Graham, MD, MPH, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Overall much improved. Suggests/comments follow.

Abstract

Clarify that this was among clinic attendees with acute illness. Dates are typically spelled out, but leave this style issue to the editors. Could consider simplifying abstract with regards to the categories of symptoms- since participants with and without symptoms the proportion offered testing was the same, why not just say among participants with any TB symptoms (especially since there appeared to be no difference among each specific symptom).

Agree with the conclusion of the Abstract.

Introduction

-Perhaps mention that Malawi is not one of the 7 countries to meet this 90/90/90 target.

-Add reference for ROOT and oral testing

Methods

-Provide reference of the Malawi national HIV Programme guidelines.

-Be explicit that patients with known HIV on ART were excluded in the Methods.

-Research assistant should be lower case I believe.

-What does opportunistic manner mean?

-Please be consistent with references either before or after a period.

-Not sure why there is a page break after Data and reproducability and Results?

Results

-Provide % for the 276 attenders who were HIV+ on ART that were excluded.

-Strikingly low offer of HIV testing (27.6%). (comment only)

-Striking that participants with a previous history of TB weren't offered HIV testing. (comment only).

-Among those offered but not tested, what was the reason?

Discussion

-Please be careful with punctuation (2 periods at end of firs sentence in Discussion)

-Seems important to point out in the first paragraph of the discussion that this low rate of testing is despite the national guideline recommendations.

-ROOT already defined in Introduction, consider using only abbreviation here.

-Were there test kit stockouts during the time? It's mentioned as a potential reason, but no further discussion.

-Although oral testing is a fantastic idea- why do the authors think this would increase testing? What does semi-supervised mean in regards to oral testing?

References

-Still has inconsistent formatting with references (some with hanging indent, some not).

-I'm a bit surprised that one of the national guideline referenced is from 2012.

Table 1

-Please use consistent capitalization for row headers.

-What are the numbers separated by a comma? Are they IQR? Ranges? Please specific in the table.

Table 2

Define WAIC

Reviewer \#2: authors may want to check the following added sentence in their discussion:

\"Qualitative research has suggested that patients often wish to know their status due a

period of health and therefore may be motivated to test themselves\"

Not clear what is meant by a period of health

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Eduard Sanders

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236407.r004

Author response to Decision Letter 1

25 Jun 2020

RESPONSE TO REVIEWER 1's COMMENTS

Comment 1:

Abstract

Clarify that this was among clinic attendees with acute illness. Dates are typically spelled out, but leave this style issue to the editors. Could consider simplifying abstract with regards to the categories of symptoms- since participants with and without symptoms the proportion offered testing was the same, why not just say among participants with any TB symptoms (especially since there appeared to be no difference among each specific symptom).

Thank you to the reviewer for these comments. In response additional clarification has been added to the abstract that these were participants with acute illness.

"In a prospective cohort study in Bangwe primary care clinic, Blantyre, Malawi, all adults (18 years or older) presenting with an acute illness were screened for TB symptoms (cough, fever, night sweats, weight loss)."

As suggested by the reviewer we have removed the percentages for each individual condition to make the abstract more readable. We have included an additional line in the text to explain that there was no difference between each symptoms.

"The proportions offered testing were similar among participants with and without TB symptoms (any TB symptom: 29.0% vs. 25.7%). This was consistent for each individual symptom; cough, weight loss, fever and night sweats."

Comment 2:

Agree with the conclusion of the Abstract.

Thank you for these positive comments.

Comment 3:

Introduction

Perhaps mention that Malawi is not one of the 7 countries to meet this 90/90/90 target.

The authors agree that providing additional clarity here will add clarity for the reader. Therefore an additional sentence is added.

"Malawi is among the large proportion of countries still striving to reach these targets."

Comment 4:

Add reference for ROOT and oral testing

Thank you. We have included references for each as follows.

ROOT: Silvestri et al. A comparison of HIV detection rates using routine opt-out provider-initiated HIV testing and counseling versus a standard of care approach in a rural African setting. J Acquir Immune Defic Syndr. 2011

Oral testing: Choko et al. 2015. Uptake, Accuracy, Safety, and Linkage into Care over Two Years of Promoting Annual Self-Testing for HIV in Blantyre, Malawi: A Community-Based Prospective Study. PLoS Med.

Comment 5:

Methods

-Provide reference of the Malawi national HIV Programme guidelines.

Thank you. This reference has now been included.

"Reference 3: Ministry of Health of Malawi. Malawi HIV Testing Services Guidelines. Lilongwe; 2016"

Comment 6:

-Be explicit that patients with known HIV on ART were excluded in the Methods.

Thank you. We have clarified this in the Methods:

"Participants with known HIV-positive status who were already taking ART were excluded from the analysis."

Comment 7:

-Research assistant should be lower case I believe.

We are in agreement that these should be described in lower case and this change has been made.

Comment 8:

-What does opportunistic manner mean?

We have provided further clarity to this methodology as below.

"Research assistants were also based at the two clinic outpatient department exits, where they identified adults leaving the department and invited them to participate in an exit interview. The layout of the clinic is such that all participants exiting the clinic would pass the research assistants. Though researchers tried to selected as many patients as possible, due to limitations in the number of research assistants not all participants completed exit interview."

Comment 9:

-Please be consistent with references either before or after a period.

This has been addressed and references now always appear after periods. Thank you.

Comment 10:

-Not sure why there is a page break after Data and reproducability and Results?

This has been removed.

Comment 11:

Results

-Provide % for the 276 attenders who were HIV+ on ART that were excluded.

This has now been included in the manuscript.

"A total of 276 (11.5%) clinic attenders reported that they were HIV positive and taking ART and were exclude from regression modelling."

Comment 12:

-Strikingly low offer of HIV testing (27.6%). (comment only)

-Striking that participants with a previous history of TB weren't offered HIV testing. (comment only).

Thank you for these comments. These show the suboptimal rates of testing offer in high risk populations which the manuscript aims to highlight.

Comment 13:

-Among those offered but not tested, what was the reason?

Rationale for participant's non-completion of HIV testing was not evaluated in this study. A proportion of these patients may not have refused testing but instead were unable to undergo testing due to limited numbers of health-care workers or test kits.

"These stated limitations may account for the population of patients in our study who were offered HIV testing but did not undergo a test."

Comment 14:

Discussion

-Please be careful with punctuation (2 periods at end of firs sentence in Discussion)

This has been addressed.

Comment 15:

-Seems important to point out in the first paragraph of the discussion that this low rate of testing is despite the national guideline recommendations.

Thank you for this suggestion. A sentence has been added to the first paragraph of the discussion to highlight this key issue

"This highlights lack of implementation of national guidelines, which state that all patients attending an outpatient appointment should be offered an HIV test."

Comment 16:

-ROOT already defined in Introduction, consider using only abbreviation here.

Corrected as recommended

Comment 17:

-Were there test kit stockouts during the time? It's mentioned as a potential reason, but no further discussion.

Thank you for this suggestion. No, there were no stock-outs during the study period.

Comment 18:

-Although oral testing is a fantastic idea- why do the authors think this would increase testing? What does semi-supervised mean in regards to oral testing?

A large body of evidence is now supporting HIV self-testing as a complementary strategy to increase uptake of HIV testing. Semi-supervised means that a health worker is in attendance, or available, should the patient require additional help in performing or interpreting the test themselves.

Comment 19:

References

-Still has inconsistent formatting with references (some with hanging indent, some not).

Thank you. This has been addressed.

Comment 20:

-I'm a bit surprised that one of the national guideline referenced is from 2012.

Thank you. These are the most recent TB screening guidelines. WHO is currently updating its TB screening guidelines, and we anticipate updated Malawi guidelines thereafter.

Comment 21:

Table 1

-Please use consistent capitalization for row headers.

This has been addressed

Comment 22:

-What are the numbers separated by a comma? Are they IQR? Ranges? Please specific in the table.

Thank you. These are ranges (min and max), as indicated in the table row legend.

Comment 23:

Table 2

Define WAIC

Thank you. WAIC is the Watanabe-Akaike information criteria. This is a standard information criteria for assessing model fit.

RESPONSE TO REVIEWER TWO'S COMMENTS:

Comment 1

Authors may want to check the following added sentence in their discussion:

\"Qualitative research has suggested that patients often wish to know their status due a period of health and therefore may be motivated to test themselves\"

Not clear what is meant by a period of health

This sentence has been changed and now reads.

"Qualitative research has suggested that patients who noticed a decline in their health, may wish to know their status and therefore may be motivated to test themselves."
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Submitted filename: Response to Reviewers June 2020.docx
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Dear Dr. Mair,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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Susan Marie Graham, MD, MPH, PhD

Academic Editor

PLOS ONE
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Dear Dr. Mair:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Susan Marie Graham

Academic Editor
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